Continue to develop resources, capabilities and partnerships to advance data-driven drug repositioning and combination therapy.
Support the development of an AD connectivity Map (CMap), whereby genes, drugs, and disease states are connected by common gene and other omics expression signatures in disease-relevant cell types (iPSC neurons, microglia, astrocytes, mixed cell cultures, organoids).
Establish an academic/industry partnership where industry partners can submit failed phase II/III compounds for molecular profiling that would enable computational drug repositioning analysis for AD.
Improve the regulatory environment for repurposing of drugs and combination therapies to obtain longer periods of exclusivity similar to those for orphan indications.
- Research Implementation Area
- Drug Repurposing and Combination Therapy Development
- In Progress
- PAR-20-156: Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer’s Disease (R01 Clinical Trial Optional)